BioSight: Funding, Investors & Team (Oct 2026)
BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments.
BioSight has raised $27.0M across 1 funding round on record, the most recent an undisclosed round of $27.0M announced in Dec 2020.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioSight Company Profile and Key Stats
Latest funding round on record: Dec 2020.
BioSight Funding Rounds
BioSight Founders and Leadership Team
Contact details for the BioSight team: 1 of 1 has an email address on file.
Start 14-day free trial →BioSight Funding Compared to Other Biotechnology Startups
BioSight's latest round of $27.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioSight in Biotechnology and Carmiel
Companies Similar to BioSight
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
BioSight Funding FAQs
What does BioSight do?
BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments.
How much funding has BioSight raised?
BioSight has raised $27.0M across 1 round on record. The most recent is an undisclosed round of $27.0M announced in Dec 2020.
When did BioSight last raise funding?
BioSight's most recent funding round on record is an undisclosed round of $27.0M, announced in Dec 2020.
Who is the CEO of BioSight?
Ruth Ben Yakar is listed as CEO at BioSight.
Where is BioSight headquartered?
BioSight is based in Carmiel, Hazafon, Israel.
How many employees does BioSight have?
BioSight is in the 1-10 employee band.
How does BioSight's funding compare to other Biotechnology startups?
BioSight's latest round of $27.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's BioSight Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioSight is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.